EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Classification of anticancer drugs: an update with FDA- and EMA-approved drugs

Lorena Ostios-Garcia, Daniel Martínez Pérez, Beatriz Castelo, Noelia Hernández Herradón, Pilar Zamora, Jaime Feliu, Enrique Espinosa

Cancer and Metastasis Reviews · 2024

DOI: 10.1007/s10555-024-10188-5 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer and Metastasis Reviews, 2024. Verfasst von Lorena Ostios-Garcia und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain. Hauptthemen laut MEDLINE: Antineoplastic Agents, United States Food and Drug Administration, Drug Approval, Neoplasms. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad Autónoma de Madrid.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anticancer systemic therapy comprises a complex and growing group of drugs. Some of the new agents with novel mechanisms of action that have appeared are difficult to fit in the groups of classical chemotherapy, hormones, tyrosine-kinase inhibitors, and monoclonal antibodies. We propose a classification based on two levels of information: the site of action and the mechanism of action. Regarding the former, drugs can exert their action in the tumor cell, the tumor vasculature, the immune system, or the endocrine system. The mechanism of action refers to the molecular target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsUnited States Food and Drug AdministrationDrug ApprovalNeoplasmsHumansUnited StatesEuropeAnimals

Stichwörter der Autor:innen

Antineoplastic agentsChemotherapyClassificationImmunotherapyMonoclonal antibodiesTyrosine-kinase inhibitors

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain.
  • Universidad Autónoma de Madrid, School of Medicine - Department of Medical Oncology, Hospital Universitario La Paz, Madrid - CIBERONC, Madrid, Spain.
  • Universidad Autónoma de Madrid, School of Medicine - Department of Medical Oncology, Hospital Universitario La Paz, Madrid - CIBERONC, Madrid, Spain. enrique.espinosa@uam.es.

Förderung

  • Universidad Autónoma de Madrid

Zitieren

APA

Ostios-Garcia, L., Pérez, D. M., Castelo, B., Herradón, N. H., Zamora, P., Feliu, J., & Espinosa, E. (2024). Classification of anticancer drugs: an update with FDA- and EMA-approved drugs. Cancer and Metastasis Reviews. https://doi.org/10.1007/s10555-024-10188-5

Vancouver

Ostios-Garcia L, Pérez DM, Castelo B, Herradón NH, Zamora P, Feliu J, et al. Classification of anticancer drugs: an update with FDA- and EMA-approved drugs. Cancer and Metastasis Reviews. 2024. doi:10.1007/s10555-024-10188-5

BibTeX
@article{OstiosGarcia2024,
  author = {Ostios-Garcia, Lorena and Pérez, Daniel Martínez and Castelo, Beatriz and Herradón, Noelia Hernández and Zamora, Pilar and Feliu, Jaime and Espinosa, Enrique},
  title = {Classification of anticancer drugs: an update with FDA- and EMA-approved drugs},
  journal = {Cancer and Metastasis Reviews},
  year = {2024},
  doi = {10.1007/s10555-024-10188-5}
}
Kostenlos starten →